Anticoagulant effects of hirulog, ∗∗Hirulog™ brand direct thrombin inhibitor. a novel thrombin inhibitor, in patients with coronary artery disease
Christopher P. Cannon(Brigham and Women's Hospital), Peter Ganz(San Francisco General Hospital), Arthur McAllister(Harvard University), Karen Eddings(Brigham and Women's Hospital), Burt Adelman(Unknown), Dorinda George(Brigham and Women's Hospital), John M. Maraganore(Biogen (United States)), Andrew P. Selwyn(Biogen (United States)), Irving H. Fox(Takeda (United States)), Eugene Braunwald(Mass General Brigham), Joseph Loscalzo(Broad Institute)
Cited by 82
Related Papers
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2011|1.9k
Circadian Variation in the Frequency of Onset of Acute Myocardial Infarction
|New England Journal of Medicine|1985|1.9k